We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
Fondaparinux
From WikEM
Contents
Administration
- Type: Anticoagulant
- Dosage Forms:
- Routes of Administration: Subcutaneous, IV
- Common Trade Names: Arixtra
Adult Dosing
- STEMI, NSTEMI: 2.5mg daily
- Acute DVT, PE: 5-10mg subq daily until warfarin therapeutic
- VTE prophylaxis: 2.5mg subq daily
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: contraindicated if CrCl <30, use with caution if CrCl 30-50
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Active major bleeding
- Bacterial endocarditis
- Thrombocytopenia associated with antiplatelet antibody when tested with fondaparinux
- Weight <50kg
- Severe renal impairment (CrCl <30)
Adverse Reactions
Serious
- Bleeding, anemia, thrombocytopenia
- Epidural hematoma, spinal subdural hematoma
Common
- Injection site reaction, rash
- Fever
Pharmacology
- Half-life: 17-21h
- Metabolism:
- Excretion: Renal
Mechanism of Action
- Inhibits antithrombin III, neutralizing Factor Xa (similar to low molecular weight heparins)
